MedPath

EVALUATION AND COMPARISON OF SAFETY AND EFFICACY OF TWO ANTI-ACNE TEST PRODUCTS ON MILD TO MODERATE ACNE.

Not Applicable
Registration Number
CTRI/2011/04/001662
Lead Sponsor
OPLO
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Other (Terminated)
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Voluntary men/women with 4 acne lesions with nearly the same severity score and similar maturation age (per history) on the entire face.

2.Age between 18 â?? 25 years.

3.No treatment for acne in the past 1 month

4.Phototype III and IV.

5.All skin types (greasy, normal) except known significant sensitive skin.

6.Accepting not to use products with the same end benefit during the entire study duration.

7.For whom the Investigator considers that the compliance will be correct.

8.Cooperating, informed of the need and duration of the examinations, and ready to comply with protocol procedures.

9.Having signed a Consent Form and will be once informed orally and in writing of all information concerning the study procedures and study objectives.

Exclusion Criteria

1.Pregnant women and lactating women. In any case of suspicion a pregnancy test shall be preformed.

2.History suggestive of any hormonal problems.

3.History of allergic dermatitis or contact allergy to cosmetics,

4.Subjects on oral retinoid since the past 3 months.

5.Hypersensitivity to any cosmetic product, raw material.

6.Any clinically significant systemic or cutaneous disease, which may interfere with study treatments or procedures.

7.Subjects on any medical treatment either systemic or topical which may interfere with the performance of the study treatment (presently or in the past 1 month).

8.Subject in an exclusion period or participating in another similar cosmetic or therapeutic trial.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.Dermatological Grading of acne lesions.Timepoint: The study will be conducted over a period of 40 hours and would involve 3 visits- <br/ ><br> [Visit 1 (0 hour), Visit 2 (16 Hours) and Visit 3(40 Hours)]. <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
1.Dermatological evaluation of cutaneous tolerance at all visits.Timepoint: 1.0 hour, 16 Hours and 40 Hours.
© Copyright 2025. All Rights Reserved by MedPath